- In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had expanded the approval of Praluent (alirocumab) to include pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). The approval allows its use as an adjunct to diet and other LDL-C-lowering therapies in this younger population
- In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had expanded the indication for Praluent (alirocumab), approving its use as an adjunct to diet and other LDL-C-lowering therapies for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH)
